Clinical Trial

Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICC

Name: Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICC — clinical trial record (NCT06648525)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is a multicenter, open label, randomized, two-arm clinical study to observe and evaluate the efficacy and safety of adebrelimab combined with irinotecan liposomes, 5-fluorouracil, calcium folinate ± lenvatinib as first-line treatment for advanced intrahepatic cholangiocarcinoma (ICC).

Trial Details

NCT Number	NCT06648525
Lead Sponsor	Harbin Medical University
Conditions	Intrahepatic Cholangiocarcinoma (Icc)
Enrollment	68 participants
Start Date	2024-10
Primary Completion	2027-04 (estimated)
Study Completion	2028-04 (estimated)
Updated on ClinicalTrials.gov	2024-10-18